{"id":4142,"company":{"country":"CH","currency":"USD","exchange":"SWISS EXCHANGE","ipo":"2001-05-07","marketCap":195259.015625,"name":"Novartis AG","phone":"41613241111","outstanding":1956.4862060546875,"symbol":"NVS","website":"https://www.novartis.com/","industry":"Pharmaceuticals"},"price":111.995,"year":2024,"month":8,"day":2,"weekday":"Friday","title":"Historical Stock Price Performance of Novartis AG during Significant Market Events","date":"2024-08-02","url":"/posts/2024/08/02/NVS","content":[{"section":"Market Crash of 2008","text":"During the global financial crisis in 2008, Novartis AG's stock experienced a significant decline along with the broader market. The crash was triggered by the collapse of Lehman Brothers in September 2008 and resulted in a severe economic downturn. Novartis' stock price dropped from around $56 in August 2008 to approximately $35 by November 2008, reflecting a decline of around 38%."},{"section":"Market Recovery and Rally","text":"Following the market crash of 2008, Novartis AG, like many other companies, saw a recovery in its stock price. As the global economy stabilized, investor confidence increased, leading to a rally in the stock market. Novartis' stock price gradually climbed from its low point in November 2008 and reached a peak of around $71 in April 2011, marking a significant gain of approximately 103% from the bottom reached during the crash."},{"section":"European Debt Crisis","text":"During the European debt crisis in 2010-2012, Novartis AG's stock price faced some volatility. The crisis, which originated in Greece and later affected several other European countries, created uncertainty in global markets. Novartis' stock price fluctuated within a range of $51 to $63 during this period, reflecting the cautious sentiment among investors."},{"section":"Market Correction of 2018","text":"In 2018, global markets experienced a significant correction, driven by concerns over rising interest rates and trade tensions between the United States and China. Novartis AG's stock price also declined during this period, dropping from around $86 in January to approximately $74 by December 2018. This correction represented a decline of around 14%."},{"section":"COVID-19 Pandemic Impact","text":"The COVID-19 pandemic, which began in early 2020, had both positive and negative effects on Novartis AG's stock price. Initially, the stock faced a decline as the markets reacted to the uncertainty and economic disruption caused by the pandemic. However, as the pharmaceutical industry played a crucial role in developing vaccines and treatments, Novartis' stock price recovered and even reached new all-time highs. As of October 2021, the stock price was around $92, demonstrating resilience and positive investor sentiment in the face of the pandemic."}],"tags":["LongSignals","Long","Pharmaceuticals"],"news":[{"category":"company","date":1722587641,"headline":"Q2 2024 Ionis Pharmaceuticals Inc Earnings Call","id":129095318,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"NVS","publisher":"Yahoo","summary":"Q2 2024 Ionis Pharmaceuticals Inc Earnings Call","url":"https://finance.yahoo.com/news/q2-2024-ionis-pharmaceuticals-inc-083401992.html"},{"category":"company","date":1722480600,"headline":"Novartis sues FDA for approving Entresto generic","id":129089907,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3581740704"},{"category":"company","date":1722465600,"headline":"Artisan Global Value Fund Q2 2024 Commentary","id":129053363,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399575283/image_1399575283.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"During Q2 2024, the Artisan Global Value Fund (Investor Class) returned 1.5%. Click here to read the full fund commentary.","url":"https://seekingalpha.com/article/4708903-artisan-global-value-fund-q2-2024-commentary"},{"category":"company","date":1722337200,"headline":"Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update","id":129001659,"image":"https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081","symbol":"NVS","publisher":"Yahoo","summary":"– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novar","url":"https://finance.yahoo.com/news/arvinas-reports-second-quarter-2024-110000118.html"},{"category":"company","date":1722328561,"headline":"Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges","id":129002115,"image":"","symbol":"NVS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4707941-legend-biotechs-promising-car-t-therapies-face-valuation-and-cash-burn-challenges"},{"category":"company","date":1722327144,"headline":"FDA grants priority review for Novartis’ leukaemia treatment","id":128999349,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/07/Novartis_shutterstock_1940836891.jpg","symbol":"NVS","publisher":"Yahoo","summary":"The decision is based on the data from the Phase III ASC4FIRST clinical trial.","url":"https://www.pharmaceutical-technology.com/news/fda-novartis-leukaemia-treatment/"},{"category":"company","date":1722315608,"headline":"TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits Resistance","id":128999077,"image":"","symbol":"NVS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4707904-tg-therapeutics-upcoming-q2-pressure-on-briumvi-to-perform-as-share-price-hits-resistance"},{"category":"company","date":1722257580,"headline":"Novartis' Scemblix granted FDA Priority Review status for front-line CML","id":128992774,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3576600195"},{"category":"company","date":1722255579,"headline":"AbbVie: Growth Is Still A Better Choice","id":128984439,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1127277566/image_1127277566.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"AbbVie's impressive Q2 2024 financial results show surging sales in immunology and neuroscience. Read why I continue to cover ABBV stock with a 'Buy' rating.","url":"https://seekingalpha.com/article/4707698-abbvie-growth-is-still-a-better-choice"},{"category":"company","date":1722238080,"headline":"Novartis receives FDA priority review for CML in adults","id":129022181,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3576988252"},{"category":"company","date":1721994480,"headline":"Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment","id":128931467,"image":"https://media.gettyimages.com/id/2161144503/photo/hands-lab-and-medical-research-with-tablet-science-and-internet-for-breakthrough-in-medicine.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=rSeqfu2rWoglg7VuNtvJ3532xcENZiabU2Lmsbh19n4=","symbol":"NVS","publisher":"SeekingAlpha","summary":"Stay informed about the latest developments in spinal muscular atrophy and obesity treatments, with a projected market growth reaching billions by 2032.","url":"https://seekingalpha.com/article/4707148-biohaven-taldefgrobep-alfa-might-have-a-place-beyond-sma-treatment"},{"category":"company","date":1721985300,"headline":"Aristotle International Equity ADR Q2 2024 Commentary","id":128929273,"image":"","symbol":"NVS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4707100-aristotle-international-equity-adr-q2-2024-commentary"},{"category":"company","date":1721895558,"headline":"Dren Bio and Novartis link on bispecific antibodies for cancer","id":128904334,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/07/Novartis-shutterstock_2210307289.jpg","symbol":"NVS","publisher":"Yahoo","summary":"Dren Bio is eligible to receive $2.85bn in preclinical, clinical, regulatory and commercial milestone payments.","url":"https://www.pharmaceutical-technology.com/news/dren-bio-novartis-antibodies-cancer/"},{"category":"company","date":1721831160,"headline":"Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?","id":128881071,"image":"https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","symbol":"NVS","publisher":"Yahoo","summary":"On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.","url":"https://finance.yahoo.com/news/beat-cards-incyte-incy-q2-142600358.html"},{"category":"company","date":1721820240,"headline":"Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board","id":128883830,"image":"https://www.biopharmadive.com/imgproxy/aFO49QT1-ytbqrjsghNN87eKIlQQL6Xv-4smpw2yyUw/g:nowe:909:0/c:6097:3444/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0ODM5MjE3OTMuanBn.webp","symbol":"NVS","publisher":"Yahoo","summary":"The Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.” Elsewhere, Geron is losing its commercial chief and Biovectra will sell to Agilent for $925 million.","url":"https://www.biopharmadive.com/news/novartis-dren-bio-langer-moderna-board-biovectra-agilent/722086/"},{"category":"company","date":1721808120,"headline":"Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer","id":128891241,"image":"","symbol":"NVS","publisher":"Business Wire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=mja13of2u6"},{"category":"company","date":1721785320,"headline":"Novartis to collaborate with Dren Bio on bispecific antibody therapies","id":128891243,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3570101621"},{"category":"company","date":1721763136,"headline":"Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking","id":128866392,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1871083321/image_1871083321.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Sangamo Therapeutics is almost out of cash, and at risk of bankruptcy.Â Learn the reasons whyÂ an investment in the SGMO stock is unsuitable right now.","url":"https://seekingalpha.com/article/4705968-sangamo-therapeutics-a-bust-or-billion-dollar-valuation-in-the-remaking"},{"category":"company","date":1721737020,"headline":"Novartis AG (NOVN) Gets a Hold from Berenberg Bank","id":128847412,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3567885764"},{"category":"company","date":1721719800,"headline":"Novartis price target raised by CHF 9 at Berenberg","id":128891244,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3568973833"},{"category":"company","date":1721702700,"headline":"AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife","id":128857897,"image":"","symbol":"NVS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3567973637"},{"category":"company","date":1721653211,"headline":"These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar","id":128831674,"image":"https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c","symbol":"NVS","publisher":"Yahoo","summary":"Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.","url":"https://finance.yahoo.com/news/2-medical-stocks-could-beat-130011272.html"},{"category":"company","date":1721650759,"headline":"Johnson \u0026 Johnson: Seriously Undervalued At Peak Pessimism","id":128832494,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220083268/image_1220083268.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Johnson \u0026 Johnson's Q2 results exceeded expectations, driven by strong oncology and immunology sales. Read why I continue to cover JNJ stock with a Strong Buy.","url":"https://seekingalpha.com/article/4705518-johnson-and-johnson-seriously-undervalued-at-peak-pessimism"},{"category":"company","date":1721640059,"headline":"Healthcare 2024 Second Half Outlook","id":128830586,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"While the healthcare index underperformed the broader market, there are favorable indications for the second half. Read more to see my thoughts on the sector.","url":"https://seekingalpha.com/article/4705471-healthcare-2024-second-half-outlook"},{"category":"company","date":1721541600,"headline":"Here are Big Pharma’s leading blockbuster makers","id":128822866,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3565745324"},{"category":"company","date":1721447403,"headline":"Novartis: Another Beat, Another Raise","id":128808929,"image":"https://media.gettyimages.com/id/2159351681/photo/view-of-novartis-company-office-with-logo-sign-biotech-industry.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=ebMvNXL6EvVm7XVhbFUWPvf1x5AaBih5VVgVXarDtZw=","symbol":"NVS","publisher":"SeekingAlpha","summary":"Investors can benefit from Novartis' strong revenue growth, margin expansion, buybacks, dividends, and raised guidance. Read more on NVS stock here.","url":"https://seekingalpha.com/article/4705254-novartis-another-beat-another-raise"},{"category":"company","date":1721397360,"headline":"Ionis (IONS) Completes Enrolment for Rare Disease Drug Study","id":128790537,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"NVS","publisher":"Yahoo","summary":"Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.","url":"https://finance.yahoo.com/news/ionis-ions-completes-enrolment-rare-135600733.html"},{"category":"company","date":1721395560,"headline":"Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data","id":128790538,"image":"https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3","symbol":"NVS","publisher":"Yahoo","summary":"J\u0026J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.","url":"https://finance.yahoo.com/news/pharma-stock-roundup-jnj-nvs-132600258.html"},{"category":"company","date":1721389620,"headline":"Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug","id":128791487,"image":"https://www.biopharmadive.com/imgproxy/aFO49QT1-ytbqrjsghNN87eKIlQQL6Xv-4smpw2yyUw/g:nowe:909:0/c:6097:3444/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0ODM5MjE3OTMuanBn.webp","symbol":"NVS","publisher":"Yahoo","summary":"Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.","url":"https://www.biopharmadive.com/news/lilly-morphic-novartis-morphosys-pelabresib-parker-cancer-agenus/721835/"},{"category":"company","date":1721384154,"headline":"Why Novartis Deserves Your Attention After Q2 2024 Results","id":128789025,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291337766/image_1291337766.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Novartis AG posted impressive Q2 2024 results with strong sales in oncology and heart medication. Read the factors leading to a buy rating for NVS stock.","url":"https://seekingalpha.com/article/4705095-why-novartis-deserves-your-attention-after-q2-2024-results"},{"category":"company","date":1721378940,"headline":"Novartis AG (NOVN) Gets a Buy from Kepler Capital","id":128814744,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3564617879"},{"category":"company","date":1721367360,"headline":"Novartis AG (NOVN) Receives a Hold from J.P. Morgan","id":128800073,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3563657505"},{"category":"company","date":1721362080,"headline":"Novartis just downgraded at Deutsche Bank, here's why","id":128800074,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3563598223"},{"category":"company","date":1721359680,"headline":"Deutsche Numis downgrades Novartis AG (NOVN) to a Hold","id":128800075,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3563577661"},{"category":"company","date":1721354340,"headline":"Barclays Keeps Their Sell Rating on Novartis AG (NOVN)","id":128800076,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3563521650"},{"category":"company","date":1721351100,"headline":"Novartis AG (NVS) Q2 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...","id":128800077,"image":"","symbol":"NVS","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3563490076"}]}